Company / Return on Equity (ROE)
Syndax Pharmaceuticals Inc Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-441.6%
FY2025
5-year range
-441.6% / -31.9%
FY2021-FY2025
Trend
-299.2%
vs FY2024
Sector context
#188 of 190
Health Care
What the data says
Syndax Pharmaceuticals Inc reports negative total equity of -441.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-441.6% in FY2025 with a 5-year CAGR of -302.2%.
Declined from -37.8% to -441.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -409.7pp
- 5-Year Change
- -302.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 190This company -441.6% Sector average -50.3%
▼
-777.7% below sector average
Key checks
Key Insights
- Syndax Pharmaceuticals Inc's return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 299.2% year-over-year.
- Currently 391.3pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -441.6% | -299.2% |
| FY2024 | -110.6% | -192.8% |
| FY2023 | -37.8% | -18.2% |
| FY2022 | -31.9% | +82.0% |
| FY2021 | -177.4% | -27.2% |
| FY2020 | -139.4% | -139.2% |
| FY2019 | -58.3% | -10.3% |
| FY2018 | -52.9% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026